Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy

Prolonged chronic phase in chronic myelogenous

leukemia after homoharringtonine therapy

LI Yu-feng;DENG Zhi-kui;XUAN Heng-bao;ZHU Jia-bin;DING Bang-he;LIU Xiao-ning;CHEN Bao-an

【期刊名称】《中华医学杂志（英文版）》 【年(卷),期】2009(122)012

【摘要】Background Homoharringtonine (HH'r) is effective in treating late stage chronic myelogenous leukaemia (CML), but little is known about long term maintenance during complete cytogenetic response. Long term efficacy and toxicity profiles of low dose HHT were evaluated in this study.Methods One hundred and six patients with CML received 1.5 mg/m2 of HHT alone by continuous daily infusion for seven to nine days every four weeks. Of 79 patients in the control group, 31 were treated with interferon α (IFN-α) and 48 with hydroxycarbamide. For 17 patients who failed to achieve cytogenetic response within 12 months' treatment of IFN-α, HHT was administered. Quantitative RT-PCR was used to detect the BCR-ABL mRNA expression in 36 Philadelphia positive CML patients enrolled after 2007. Haematological and cytogenetic responses were evaluated in all patients at the 12th month of follow-up. Long term efficacy was assessed in a follow-up with a median time of 54 months (12 months-98 months).Results After 12 months of therapy, cytogenetic response rate of the HHT, IFN-α and